Induction of cytotoxic T lymphocyte development from murine thymocytes by IL-1 and IL-6

Henri Ford, Rosemary A. Hoffman, Stewart Wang, Richard L. Simmons

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cytotoxic T lymphocytes (CTL) are believed to play an important role in the regression of advanced malignancies in response to adoptive immunotherapy with interleukin-2 (IL-2) and lymphokine-activated killer cells or tumor-infiltrating lymphocytes. Because the current limitations to the use of adoptive immunotherapy are the IL-2 dose-dependent toxicities and the difficulty in expanding the effector cell population, recent investigations have focused on the development of newer methods for generating CTL in vitro. IL-1 and IL-6 have been shown to synegistically promote thymocyte proliferation; however, their effect on CTL development has not been studied. We investigated the ability of these two cytokines to induce CTL development from immature thymocytes. Thymocytes from 5-week-old BALB c mice were cultured for 72 hours in the presence of Con A and recombinant IL-1, IL-6, or IL-1 plus IL-6. Cytotoxicity against 51Cr-labeled P815 target cells was then measured in the presence of submitogenic doses of PHA. Neither IL-1 nor IL-6 induced a significant number of CTL from immature thymocytes. However, these two cytokines synergistically induced maximal CTL development. The monoclonal antibody to IL-4 completely abrogated CTL development induced by IL-1 and IL-6, but antibody to the IL-2 receptor had no effect. The data suggest that IL-1 and IL-6 can provide an additional method for in vitro CTL generation in adoptive immunotherapy of advanced tumors.

Original languageEnglish (US)
Pages (from-to)397-400
Number of pages4
JournalJournal of Pediatric Surgery
Volume26
Issue number4
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Cytotoxic T-Lymphocytes
Thymocytes
Interleukin-1
Interleukin-6
Adoptive Immunotherapy
Interleukin-2
Cytokines
Tumor-Infiltrating Lymphocytes
Lymphokine-Activated Killer Cells
Interleukin-2 Receptors
Interleukin-4
Neoplasms
Monoclonal Antibodies
Antibodies
Population

Keywords

  • Adoptive immunotherapy
  • cytotoxic T lymphocytes
  • IL-1
  • IL-6

ASJC Scopus subject areas

  • Surgery

Cite this

Induction of cytotoxic T lymphocyte development from murine thymocytes by IL-1 and IL-6. / Ford, Henri; Hoffman, Rosemary A.; Wang, Stewart; Simmons, Richard L.

In: Journal of Pediatric Surgery, Vol. 26, No. 4, 01.01.1991, p. 397-400.

Research output: Contribution to journalArticle

Ford, Henri ; Hoffman, Rosemary A. ; Wang, Stewart ; Simmons, Richard L. / Induction of cytotoxic T lymphocyte development from murine thymocytes by IL-1 and IL-6. In: Journal of Pediatric Surgery. 1991 ; Vol. 26, No. 4. pp. 397-400.
@article{dc1320f0eb1443d79e958a73a396873c,
title = "Induction of cytotoxic T lymphocyte development from murine thymocytes by IL-1 and IL-6",
abstract = "Cytotoxic T lymphocytes (CTL) are believed to play an important role in the regression of advanced malignancies in response to adoptive immunotherapy with interleukin-2 (IL-2) and lymphokine-activated killer cells or tumor-infiltrating lymphocytes. Because the current limitations to the use of adoptive immunotherapy are the IL-2 dose-dependent toxicities and the difficulty in expanding the effector cell population, recent investigations have focused on the development of newer methods for generating CTL in vitro. IL-1 and IL-6 have been shown to synegistically promote thymocyte proliferation; however, their effect on CTL development has not been studied. We investigated the ability of these two cytokines to induce CTL development from immature thymocytes. Thymocytes from 5-week-old BALB c mice were cultured for 72 hours in the presence of Con A and recombinant IL-1, IL-6, or IL-1 plus IL-6. Cytotoxicity against 51Cr-labeled P815 target cells was then measured in the presence of submitogenic doses of PHA. Neither IL-1 nor IL-6 induced a significant number of CTL from immature thymocytes. However, these two cytokines synergistically induced maximal CTL development. The monoclonal antibody to IL-4 completely abrogated CTL development induced by IL-1 and IL-6, but antibody to the IL-2 receptor had no effect. The data suggest that IL-1 and IL-6 can provide an additional method for in vitro CTL generation in adoptive immunotherapy of advanced tumors.",
keywords = "Adoptive immunotherapy, cytotoxic T lymphocytes, IL-1, IL-6",
author = "Henri Ford and Hoffman, {Rosemary A.} and Stewart Wang and Simmons, {Richard L.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0022-3468(91)90985-3",
language = "English (US)",
volume = "26",
pages = "397--400",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Induction of cytotoxic T lymphocyte development from murine thymocytes by IL-1 and IL-6

AU - Ford, Henri

AU - Hoffman, Rosemary A.

AU - Wang, Stewart

AU - Simmons, Richard L.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Cytotoxic T lymphocytes (CTL) are believed to play an important role in the regression of advanced malignancies in response to adoptive immunotherapy with interleukin-2 (IL-2) and lymphokine-activated killer cells or tumor-infiltrating lymphocytes. Because the current limitations to the use of adoptive immunotherapy are the IL-2 dose-dependent toxicities and the difficulty in expanding the effector cell population, recent investigations have focused on the development of newer methods for generating CTL in vitro. IL-1 and IL-6 have been shown to synegistically promote thymocyte proliferation; however, their effect on CTL development has not been studied. We investigated the ability of these two cytokines to induce CTL development from immature thymocytes. Thymocytes from 5-week-old BALB c mice were cultured for 72 hours in the presence of Con A and recombinant IL-1, IL-6, or IL-1 plus IL-6. Cytotoxicity against 51Cr-labeled P815 target cells was then measured in the presence of submitogenic doses of PHA. Neither IL-1 nor IL-6 induced a significant number of CTL from immature thymocytes. However, these two cytokines synergistically induced maximal CTL development. The monoclonal antibody to IL-4 completely abrogated CTL development induced by IL-1 and IL-6, but antibody to the IL-2 receptor had no effect. The data suggest that IL-1 and IL-6 can provide an additional method for in vitro CTL generation in adoptive immunotherapy of advanced tumors.

AB - Cytotoxic T lymphocytes (CTL) are believed to play an important role in the regression of advanced malignancies in response to adoptive immunotherapy with interleukin-2 (IL-2) and lymphokine-activated killer cells or tumor-infiltrating lymphocytes. Because the current limitations to the use of adoptive immunotherapy are the IL-2 dose-dependent toxicities and the difficulty in expanding the effector cell population, recent investigations have focused on the development of newer methods for generating CTL in vitro. IL-1 and IL-6 have been shown to synegistically promote thymocyte proliferation; however, their effect on CTL development has not been studied. We investigated the ability of these two cytokines to induce CTL development from immature thymocytes. Thymocytes from 5-week-old BALB c mice were cultured for 72 hours in the presence of Con A and recombinant IL-1, IL-6, or IL-1 plus IL-6. Cytotoxicity against 51Cr-labeled P815 target cells was then measured in the presence of submitogenic doses of PHA. Neither IL-1 nor IL-6 induced a significant number of CTL from immature thymocytes. However, these two cytokines synergistically induced maximal CTL development. The monoclonal antibody to IL-4 completely abrogated CTL development induced by IL-1 and IL-6, but antibody to the IL-2 receptor had no effect. The data suggest that IL-1 and IL-6 can provide an additional method for in vitro CTL generation in adoptive immunotherapy of advanced tumors.

KW - Adoptive immunotherapy

KW - cytotoxic T lymphocytes

KW - IL-1

KW - IL-6

UR - http://www.scopus.com/inward/record.url?scp=0025892627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025892627&partnerID=8YFLogxK

U2 - 10.1016/0022-3468(91)90985-3

DO - 10.1016/0022-3468(91)90985-3

M3 - Article

C2 - 2056398

AN - SCOPUS:0025892627

VL - 26

SP - 397

EP - 400

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 4

ER -